Traders should monitor for the upcoming definitive proxy statement, regulatory filings, and potential competing bids. The acquisition could lead to operational synergies and revenue expansion through Danaher's global commercial infrastructure. Consider positioning for deal closure in the coming months, barring regulatory or shareholder hurdles.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $175.27entry
- T+1 · 9mo ago −0.45%α +0.47% · $174.49
- T+5 · 8mo ago +0.09%α +1.29% · $175.42
- T+20 · 8mo ago +0.99%α +8.93% · $177.00
- T+60 · 6mo ago +1.94%α −7.39% · $178.67
Price Chart
REPLAYWatch the reaction play outExecutive Summary
Danaher Corporation has announced an agreement to acquire Masimo Corporation, a medical technology company specializing in patient monitoring solutions. The DFAN14A filing consists of communications from Danaher leadership to Masimo employees, confirming the proposed transaction and expressing enthusiasm about combining the two organizations to expand global impact in diagnostics and patient care.
Key Facts
- Danaher Corporation is acquiring Masimo Corporation.
- The deal is intended to combine Danaher's diagnostics platform with Masimo's patient monitoring and acute care innovations.
- Julie Sawyer Montgomery, Executive Vice President of Danaher's Diagnostics segment, communicated directly with Masimo employees to affirm commitment and vision.
- The transaction is subject to regulatory approvals, stockholder approval, and other customary closing conditions.
- Until closing, Masimo will continue operating independently under current leadership.
Financial Impact
Deal value not disclosed in this filing, but Masimo's market cap is $9.4B as of filing date.
Risk Factors
- Failure to obtain regulatory approvals or Masimo stockholder approval.
- Potential for competing acquisition offers.
- Integration risks post-closing.
- Litigation related to the transaction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DFAN14A Filing (Primary) | 0001193125-26-082686 |
| Document: 0001193125-26-082686-index-headers.html | 0001193125-26-082686 |
| Document: 0001193125-26-082686-index.html | 0001193125-26-082686 |
| Document: 0001193125-26-082686.txt | 0001193125-26-082686 |
Track record
10 reports on MASI
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +0.39% at T+20 after the May 4, 2026 report. 3 of 4 went positive at some point.
Filters
- Oct 12, 20265w ago Institutional Cluster Bearish 4/10 No price data
- Jun 22, 202621w ago 15-12G Neutral 4/10 No price data
- Jun 10, 202622w ago 8-K Bullish 8/10 Entry $179.95 No price data
- May 4, 202628w ago 8-K Bullish 8/10 Entry $177.90 to $178.59 ▲ +0.39% −5.26% vs SPY
- Apr 21, 202630w ago Court Ruling Bearish 6/10 Entry $178.21 to $178.80 ▼ −0.33% +4.59% vs SPY
- Apr 1, 202632w ago DEFM14A Bullish 8/10 Entry $177.95 to $178.46 ▲ +0.28% −9.44% vs SPY
- Mar 18, 202634w ago PREM14A Neutral 4/10 Entry $178.51 to $177.96 ▼ −0.31% −7.93% vs SPY
- Feb 27, 202637w ago DFAN14A Bullish 9/10 Viewing Entry $175.27 to $177.00 ▲ +0.99% +8.93% vs SPY
- Jan 23, 202642w ago Court Ruling Neutral 2/10 Entry $142.48 No price data
- Jan 23, 202642w ago Court Ruling Neutral 2/10 Entry $142.48 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers